Penumbra, Inc. has announced the completion of enrollment for the STORM-PE clinical trial, a groundbreaking study evaluating the efficacy of computer assisted vacuum thrombectomy (CAVT™) using Penumbra's Lightning Flash™ combined with anticoagulation, compared to anticoagulation alone in treating acute intermediate-high risk pulmonary embolism. The trial enrolled 100 patients and aims to provide high-quality evidence on the role of CAVT in improving right heart function and clinical outcomes. The completion of enrollment marks a significant milestone in the trial, which is conducted in partnership with The PERT Consortium®. Results of the STORM-PE trial have not yet been presented. For further details, visit https://www.penumbrainc.com/storm-pe-trial.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。